Differential Serum Metabolomic Profile in Patients with Schizophrenia, Cannabis Use Disorder or Dual diagnosis
Preprint
- 23 November 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Cannabis use disorder occurs in up to 42% of subjects with schizophrenia. It has been associated with a lower age of onset of schizophrenia, more positive symptoms and a higher frequency of hospitalizations. A number of metabolomic-based studies have shown that levels of several amino acids and lipids are altered in plasma of schizophrenia patients. Similarly, different levels of various lipids, amino acids, sugars, proteins and other metabolites have been quantified in plasma of cannabis consumers, suggesting that consumption of cannabis does interfere in the regulation of further metabolic pathways. In the present study, we performed a non-targeted metabolomic approach in plasma samples of subjects with a diagnosis of schizophrenia, cannabis use disorder or dual diagnosis. The aim was to find potential biomarkers of the diseases and to gain a better understanding of the relation between cannabis abuse and the development of schizophrenia. The liquid chromatography-high resolution mass spectrometry outcomes allowed the annotation of 121 metabolites. The analysis between each group and the corresponding control samples showed a clearer clustering of the samples. The two-way ANOVA and linear analysis of the whole dataset showed that most of the analytes were differently present between the groups, but none of them seems to correlate to gender or age. It can be highlighted the presence of two endocannabinoids (palmitylethanolamide (PEA) and oleoylethanolamide (OEA)), nicotine and cotinine as biomarkers of tobacco consumption, and nor-9- carboxy-Δ9-THC as biomarker of the consumption of cannabis. Moreover, some medium chain acylcarnitines (C8/C10) share a common pattern in the three comparison groups whereas some N-acyl serines were also highlighted in some of the group comparisons. The use of this non-targeted metabolomic approach provided us a deep insight to evaluate the metabolomics profile and to uncover putative biomarkers in schizophrenia and cannabis use disorder.Keywords
All Related Versions
This publication has 47 references indexed in Scilit:
- Metabolomics to study the sublethal effects of diazepam and irbesartan on glass eels (Anguilla anguilla)Aquatic Toxicology, 2023
- ANOVA simultaneous component analysis: A tutorial reviewAnalytica Chimica Acta: X, 2020
- Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methodsAdvanced Drug Delivery Reviews, 2020
- Amitriptyline at an Environmentally Relevant Concentration Alters the Profile of Metabolites Beyond Monoamines in Gilt-Head BreamEnvironmental Toxicology and Chemistry, 2019
- Ceramide and Its Related Neurochemical Networks as Targets for Some Brain Disorder TherapiesNeurotoxicity Research, 2017
- Epigenetic Treatment of Neuropsychiatric Disorders: Autism and SchizophreniaDrug Development Research, 2016
- Phosphatidylethanolamine Metabolism in Health and Disease2016
- Evidence for disruption of sphingolipid metabolism in schizophreniaJournal of Neuroscience Research, 2008
- The membrane hypothesis of schizophreniaSchizophrenia Research, 1994
- Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophreniaNeuroscience Letters, 1980